Skip to main content
. 2023 Jun 28;83(18):3001–3012. doi: 10.1158/0008-5472.CAN-23-1313

Figure 4.

Figure 4. Irreversible Pan-ERBB inhibitor, afatinib, potentiates MRTX1133 in vivo. A, Posttreatment tumor volumes normalized to pretreatment volumes of NSG mice orthotopically injected with SUIT2 and treated for 10 days with vehicle, MRTX1133, afatinib, or combo. B, Tumor weights of mice in A. C, Tumors of mice in A imaged at necropsy. D, Posttreatment tumor volumes normalized to pretreatment volumes of NSG mice orthotopically injected with MRTXR SUIT2 and treated for 10 days with vehicle, MRTX1133, afatinib, or combo. E, Tumor weights of mice in D. F, Tumors of mice in D imaged at necropsy. G, Posttreatment tumor volumes normalized to pretreatment volumes of C57BL/6J mice orthotopically injected with parental KPC 1242 cells and treated for 10 days with vehicle, MRTX1133, afatinib, or combo. H, Tumor weights of mice in G. I, Tumors of mice in G imaged at necropsy. J, Posttreatment tumor volumes normalized to pretreatment volumes of C57BL/6J mice orthotopically injected with MRTXR KPC 1242 cells and treated for 10 days with vehicle, MRTX1133, afatinib, or combo. K, Tumor weights of mice in J. L, Tumors of mice in J imaged at necropsy. M, Survival study of C57BL/6J mice orthotopically injected with parental KPC 1242 cells and treated with vehicle, MRTX1133, afatinib, or combo. †, censored data; *, P < 0.05; **, P < 0.01; ***, P < 0.001, log-rank test. Data, mean values ± SD.

Irreversible Pan-ERBB inhibitor, afatinib, potentiates MRTX1133 in vivo. A, Posttreatment tumor volumes normalized to pretreatment volumes of NSG mice orthotopically injected with SUIT2 and treated for 10 days with vehicle, MRTX1133, afatinib, or combo. B, Tumor weights of mice in A. C, Tumors of mice in A imaged at necropsy. D, Posttreatment tumor volumes normalized to pretreatment volumes of NSG mice orthotopically injected with MRTXR SUIT2 and treated for 10 days with vehicle, MRTX1133, afatinib, or combo. E, Tumor weights of mice in D. F, Tumors of mice in D imaged at necropsy. G, Posttreatment tumor volumes normalized to pretreatment volumes of C57BL/6J mice orthotopically injected with parental KPC 1242 cells and treated for 10 days with vehicle, MRTX1133, afatinib, or combo. H, Tumor weights of mice in G. I, Tumors of mice in G imaged at necropsy. J, Posttreatment tumor volumes normalized to pretreatment volumes of C57BL/6J mice orthotopically injected with MRTXR KPC 1242 cells and treated for 10 days with vehicle, MRTX1133, afatinib, or combo. K, Tumor weights of mice in J. L, Tumors of mice in J imaged at necropsy. M, Survival study of C57BL/6J mice orthotopically injected with parental KPC 1242 cells and treated with vehicle, MRTX1133, afatinib, or combo. †, censored data; *, P < 0.05; **, P < 0.01; ***, P < 0.001, log-rank test. Data, mean values ± SD.